Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infigratinib + Tamoxifen in HR+, HER2-, FGFR-Altered Advanced Breast Cancer
NCT04504331Phase 1Terminated
- Sponsor
- Jennifer Lee Caswell-Jin
- Start
- Oct 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of infigratinib in breast cancer (3 cohorts), sponsored by Jennifer Lee Caswell-Jin. Primary endpoint: Number of Dose-limiting Toxicities at 8 weeks. Started Oct 2020; status: terminated.
02
Drugs
infigratinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04504331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04504331.